Replies to post #46230 on NorthWest Biotherapeutics Inc (NWBO)

[Know-Fear]

gnawkz, excellent summation.
"For ARGS and other BioTech companies, I find it difficult to believe that outside cell therapy contract manufacturers would shoulder so much business risk for the opportunity to produce treatments that have yet to record sales. It makes no sense to build out a large production line for a product that has not yet been approved for the marketplace. Thus why all of these BioTech companies are forced to build their own manufacturing facilities and contract out the development of the equipment and processes. Hence why I believe NWBO's situation is so unique and such a large competitive advantage."

Huge risk. And potential business for Cognate too, but its future potential business with the progression of biologic therapies. Not enough out there today to keep the lights on at Cognate.

[sentiment_stocks]

“I find it difficult to believe that outside cell therapy contract manufacturers would shoulder so much business risk for the opportunity to produce treatments that have yet to record sales. - gnawkz”

Exactly.

I can’t see why an outside company would do that either, gnawkz. Too much risk with no proof, or FDA approval.

Even if you had proof, how do you take that non-public evidence elsewhere to find someone willing to invest the tremendous amounts of money required to manufacture these vaccines on such a massive scale - and all ahead of the hoped for approval?